Satipharm is specialized in the development and manufacturing of cannabis-based health products and is Harvest One’s medical and health brand.
Satipharm’s goal is to develop cutting-edge technology and pharmaceutical-grade cannabis products for the medical and health-based cannabis markets.
Satipharm believes commercialization of its signature Gelpell® technology for cannabinoid products will transform the company into a global leader in the medical and health-based cannabis industry. Production of 10mg and 50mg Gelpell® microgel capsules began in May 2015. In 2017, Satipharm’s marketing campaign is focused on near-term growth and is distributed throughout the EU and in Australia. The company is concurrently preparing to import its products into Canada.
Satipharm is dedicated to growing its portfolio of delivery technology IP with further expansion plans targeting introduction of other formulations including THC.
For more information please visit Satipharm’s website at www.satipharm.com